Balsalazide disodium is a prodrug of mesalamine (5-aminosalicylic acid or 5-ASA) used as a first-line therapy for the treatment of mild to moderate ulcerative colitis. It is designed to deliver the active anti-inflammatory agent, mesalamine, specifically to the colon. The 750mg capsule is a standard dosage form. It acts locally in the colonic mucosa to reduce inflammation with minimal systemic absorption, making it a well-tolerated and effective option for inducing and maintaining remission in ulcerative colitis.
Adult: For active disease: 2.25g (three 750mg capsules) three times daily (6.75g total daily dose) for up to 8-12 weeks. For maintenance of remission: 1.5g (two 750mg capsules) two or three times daily (3.0g - 4.5g total daily dose).
Note: Swallow capsules whole with a full glass of water. Do not chew, break, or crush the capsules. Can be taken with or without food. Maintain adequate hydration. If a dose is missed, take it as soon as remembered, but skip if it is almost time for the next dose. Do not double the dose.
Balsalazide is a prodrug designed to deliver mesalamine (5-ASA) specifically to the colon. After oral ingestion, it remains intact in the stomach and small intestine due to its azo-bond. Upon reaching the colon, resident bacterial azoreductases cleave the azo bond, releasing the active moiety, mesalamine. Mesalamine acts topically on the colonic mucosa to exert anti-inflammatory effects. Its exact mechanism is multifactorial and includes inhibition of prostaglandin and leukotriene synthesis via blockade of cyclooxygenase and lipoxygenase pathways, scavenging of reactive oxygen species, and inhibition of nuclear factor kappa B (NF-ÎșB) activation, thereby reducing the production of pro-inflammatory cytokines like TNF-α and interleukins.
Pregnancy: Pregnancy Category B (US FDA). Animal studies show no risk, but adequate human studies are lacking. Mesalamine is considered relatively safe in pregnancy for treating active ulcerative colitis, as the disease itself poses a greater risk. Use only if clearly needed. Monitor. Indian brands advise use during pregnancy only if potential benefit justifies potential risk.
Driving: Balsalazide is unlikely to affect the ability to drive or use machines. However, patients experiencing dizziness or headache should exercise caution.
| Anticoagulants (Warfarin) | Mesalamine may have antiplatelet effects; potential increased risk of bleeding. Monitor INR closely. | Moderate |
| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs: Ibuprofen, Diclofenac) | May increase risk of nephrotoxicity (additive renal effects). Also may reduce the efficacy of balsalazide in treating colitis. | Moderate |
| Azathioprine / 6-Mercaptopurine | Concurrent use may increase risk of blood dyscrasias (leukopenia, pancytopenia). Monitor CBC regularly. | Moderate |
| Thioguanine | Increased risk of myelosuppression. Avoid combination if possible. | Major |
| Lactobacillus and other probiotics | Theoretical potential to alter colonic bacterial azoreductase activity, but clinical significance is unclear. | Minor |
| Antibiotics (broad-spectrum) | May reduce colonic bacterial flora required for activating balsalazide, potentially decreasing its efficacy. | Moderate |